Dabrafenib and steroids for the treatment of Erdheim-Chester disease with extensive CNS involvement: a case report

Carlen A Yuen,Silin Bao,Mya Sandi Aung,Rhea Shishodia,Xiao-Tang Kong
DOI: https://doi.org/10.2217/pme-2023-0137
2024-01-27
Personalized Medicine
Abstract:Erdheim-Chester disease (ECD) is an exceedingly rare non–Langerhans cell CD68 + CD1a - S100 - histiocytic multi-organ disease. Diagnosis of ECD is often delayed due to non-specific radiographic findings and heterogeneous lesional tissue. Increasingly, the role of genomic alterations is being recognized for both diagnosis and treatment of ECD. More than half of ECD patients harbor the BRAF V600E mutation. Evaluation for this mutation be can falsely negative on immunohistochemical staining and confirmation with molecular analyses is recommended. We present a case of the 44 year-old male with BRAF V600E -positive ECD treated successfully with steroids followed by single-agent dabrafenib. Erdheim-Chester disease (ECD) is an exceedingly rare type of histiocytosis (a disorder of white blood cells). The diagnosis of ECD can be challenging because tissue biopsy may not provide a definitive diagnosis. Currently, genetic mutations can be used to support both diagnosis and treatment. We present a case of the 44 year-old male with BRAF V600E -positive ECD who was treated successfully with steroids followed by dabrafenib.
pharmacology & pharmacy
What problem does this paper attempt to address?